Key result
Real-world inclisiran therapy is associated with a ~49% drop in LDL-C for secondary prevention.
Why the study?
Does the addition of inclisiran to standard lipid therapy reduce LDL-C and improve compliance with European lipid targets in secondary prevention patients?
Observational (n=55)
No
Does the addition of inclisiran to standard lipid therapy reduce LDL-C and improve compliance with European lipid targets in secondary prevention patients?
No takes yet. Share an insight, caveat, or question.
In a real-world secondary prevention setting, adding inclisiran to maximally tolerated lipid therapy reduces LDL-C by nearly 50% and helps over 40% of patients achieve ESC targets.
Smith et al. (2026) conducted an observational in Hyperlipidemia in secondary prevention (n=55). Inclisiran vs. Baseline was evaluated on Decrease in LDL-C levels. In a real-world secondary prevention setting, inclisiran therapy resulted in an average 49% decrease in LDL-C levels, enabling 41% of patients to meet ESC lipid targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: